Akeso Ivonescimab sNDA Accepted for Biliary Tract Cancer
HONG KONG, November 16, 2026 Akeso, Inc. (HKEX: 9926.HK) has announced that China’s National Medical Products Administration (NMPA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
HONG KONG, November 16, 2026 Akeso, Inc. (HKEX: 9926.HK) has announced that China’s National Medical Products Administration (NMPA) has...
ROCKVILLE, Maryland, October 29, 2026 OncoC4, Inc., a late clinical-stage biopharmaceutical company developing innovative medicines for cancer and immunological...
WAYNE, Pennsylvania, United States — October 27, 2026 Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel treatments for...
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Hong Kong, China, September 21, 2026 Akeso, Inc. has announced that nearly 30 clinical studies from its innovative biopharmaceutical...
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
